Is Asarfi Hospital overvalued or undervalued?

As of 29 October 2025, the valuation grade for Asarfi Hospital has moved from attractive to very attractive. The company is currently considered undervalued based on its strong financial ratios and favorable peer comparisons. Key ratios include a PE Ratio of 28.49, an EV to EBITDA of 15.10, and a PEG Ratio of 0.18, indicating significant growth potential relative to its price. In comparison to its peers, Asarfi Hospital stands out with a much lower PE Ratio than Max Healthcare, which has a PE of 96.03, and Apollo Hospitals at 71.83. The favorable valuation metrics suggest that Asarfi Hospital is positioned well within the industry, especially given its recent stock performance, which has significantly outpaced the Sensex, with a one-year return of 156.45% compared to the Sensex's 5.76%.